Modern Diagnostic IPO opens for subscription on December 31, 2025, and closes on January 2, 2026, with shares listing on BSE SME on January 7, 2026. The fresh issue raises ₹36.89 crore through 40.99 lakh equity shares. Modern Diagnostic & Research Centre operates 21 facilities across 8 states, offering pathology, radiology services like MRI, CT scans, and specialized tests with home collection and digital reports. The Modern Diagnostic IPO targets investors seeking growth in India’s expanding diagnostics sector driven by healthcare demand.
₹12
₹90
--
Expert Opinions
Market sentiment for Modern Diagnostic IPO leans positive, driven by 15% revenue growth to ₹78.80 crore and 55% PAT surge to ₹8.97 crore in FY 2025, alongside expanding diagnostics demand. Company strengths include 21 facilities across 8 states, integrated pathology-radiology services with 3T MRI/CT scans, home collection, and asset-light hub-spoke model yielding 23% EBITDA margins.
Risks encompass regional competition, regulatory changes in healthcare, equipment dependency, and execution in expansion. Valuation analysis for Modern Diagnostic IPO and year 2025 exhibits Return on Equity (ROE) of 55.21%, ROCE of 36.18%, and Net Asset Value (NAV) of ₹18.84. Long-term investment perspective favors sustained gains from healthcare penetration, tech upgrades via ₹20.69 crore capex, and 15% CAGR trajectory, outperforming short-term listing fluctuations.
Investor Considerations
Modern Diagnostic IPO investors should scrutinize the company’s turnaround fundamentals, with revenue climbing 15% to ₹78.80 crore and PAT jumping 55% to ₹8.97 crore in FY 2025 from prior losses. Diagnostics sector outlook brightens with rising preventive healthcare adoption and tier-II/III city penetration. Valuation analysis for Modern Diagnostic IPO in 2025 displays Price to Book Value of 4.78, PAT Margin of 11.51%, and Debt/Equity ratio of 1.07, balancing growth with controlled leverage.
Expansion via ₹20.69 crore equipment capex, working capital, and network scaling across 21 facilities promises 15% revenue CAGR. Risks cover equipment obsolescence, reimbursement policy flux, and regional rivalry. Long-term goals capture healthcare compounding and EBITDA margin uplift to 23%, surpassing short-term listing gambles prone to SME volatility.
| Date | GMP | Trend |
|---|---|---|
| 05 Jan 2026 19.16 | ₹12 | Down |
| 02 Jan 2026 20.02 | ₹16 | Up |
| 01 Jan 2026 20.19 | ₹13 | Up |
| 30 Dec 2025 19.24 | ₹11 | Up |
| 29 Dec 2025 20.01 | ₹00 | --- |
| 26 Dec 2025 20.13 | ₹00 | --- |
FAQs
Modern Diagnostic IPO Current GMP is ₹12.
Modern Diagnostic IPO Expected Returns is 13.33%.
Modern Diagnostic IPO estimated listing price is ₹102.